End Stage Renal Disease (ESRD) Drug Market 2028 By Product Type, Indication, Distribution Channel, and geography | The Insight Partners

report image

End Stage Renal Disease (ESRD) Drug Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Others); Indication (End Stage Renal Disease (ESRD) Induced Hyperparathyroidism, End Stage Renal Disease (ESRD)Induced Hyperphosphatemia, End Stage Renal Disease (ESRD) Induced Hyperkalaemia); Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), and geography

Report Code: TIPRE00016858 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

MARKET INTRODUCTION

Late-stage renal disease, also called end-stage kidney disease, occurs when chronic kidney disease (the gradual loss of kidney function) reaches an advanced state. In end-stage renal disease, kidneys are no longer able to work, as they should to meet the body's needs. At this advanced stage of kidney disease, the kidneys have lost nearly all their ability to do their job effectively, and eventually dialysis or a kidney transplant is needed to live.

MARKET DYNAMICS

Factors driving the growth of the end stage renal disease (ESRD) drug market are the high prevalence of diseases leading to chronic kidney diseases, coupled with favourable reimbursement policy for the end-stage kidney disease drugs. However, the delay in the diagnosis of chronic kidney disease is expected to hamper the growth of the market. Moreover, rising investments by major market players in end-stage kidney disease drugs is anticipated to boost the market growth.

MARKET SCOPE

The "End Stage Renal Disease (ESRD) Drug Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of end stage renal disease (ESRD) drug market with detailed market segmentation by product type, indication, and distribution channel. The end stage renal disease (ESRD) drug market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in end stage renal disease (ESRD) drug market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The end stage renal disease (ESRD) drug market is segmented on the basis of product type, indication, and distribution channel. Based on product type, the market is segmented as Calcimimetics, Vitamin D, Sterols, Potassium Binders, and Calcium-Based Phosphate Binders. On the basis of indication, the market is categorized as end stage renal disease (ESRD) induced hyperparathyroidism, end stage renal disease (ESRD) induced hyperphosphatemia, and end stage renal disease (ESRD) induced hyperkalaemia. On the basis of distribution channel, the market is categorized as hospital pharmacies, online pharmacies, and retail pharmacies

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the end stage renal disease (ESRD) drug market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The end stage renal disease (ESRD) drug market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting end stage renal disease (ESRD) drug market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the end stage renal disease (ESRD) drug market in these regions.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the end stage renal disease (ESRD) drug market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from end stage renal disease (ESRD) drug market are anticipated to have lucrative growth opportunities in the future with the rising demand for end stage renal disease (ESRD) drugin the global market. Below mentioned is the list of few companies engaged in the end stage renal disease (ESRD) drug market .

The report also includes the profiles of key players in end stage renal disease (ESRD) drug market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

  •  AbbVie Inc.
  •  Amgen
  •  AstraZeneca
  •  Sanofi
  •  Kyowa Kirin Co., Ltd.
  •  Takeda Pharmaceutical Company Limited
  •  Astellas Pharma Inc.
  •  Bayer AG
  •  Vifor Pharma Management Ltd.
  •  Akebia Drugs, Inc.

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.


Get more information on this report :

The List of Companies

1. AbbVie Inc.
2. Amgen
3. AstraZeneca
4. Sanofi
5. Kyowa Kirin Co., Ltd.
6. Takeda Pharmaceutical Company Limited
7. Astellas Pharma Inc.
8. Bayer AG
9. Vifor Pharma Management Ltd.
10. Akebia Drugs, Inc.
TIPRE00016858
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Get the Latest COVID-19 Analysis on this market


Have a Question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Speak to Analyst
Pricing
  • $3000
  • $4550
  • $6550
  • $8550

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

    Inquire for Discount